http://www.fpnotebook.com/
Intracorporal Prostaglandin E1Aka: Intracorporal Alprostadil, Caverject
- Indications
- Psychogenic Impotence
- Neurogenic Impotence
- Vasculogenic Impotence
- Contraindications
- Penile deformity (e.g Peyronie's Disease)
- Priapism risk
- Sickle Cell Disease or Sickle Cell Trait
- Leukemia
- Multiple Myeloma
- Polycythemia Vera
- Thrombocythemia
- Mechanism: Corporal smooth muscle relaxation
- Increases arterial inflow
- Decreases venous outflow
- Intracorporal Injection Preparations
- PGE1 or Alprostadil (Caverject)
- See also Intraurethral Alprostadil (MUSE)
- Papaverine
- Phentolamine
- Combinations: Alprostadil + papaverine + phentolamine
- May be more effective with less pain
- Dosage Alprostadil (titrate in physicians office)
- Dose
- Start: 2.5 ug (1.25 ug in neurogenic Impotence)
- Next: 5 ug
- Increase: 5 ug increments
- Endpoint
- Erection adequate for intercourse (duration <1 hour)
- Maximum reached (see below)
- Maximum dosing
- Maximum dose: 60 ug
- Do not exceed more than 3 times per week
- Do not exceed more than once in 24 hours
- Technique:
- Inject at dorso-lateral aspect in penis proximal third
- Alternate sides and sites for each injection
- Adverse Effects of Intracorporal Injection (41%)
- Hematoma
- Prolonged Erection exceeding 4 hours (4%)
- Priapism with Erection exceeding 6 hours (1%)
- See Priapism Reversal Protocol
- Penile Plaques (10%)
- Efficacy (Caverject)
- Success Rates: 67 to 85%
- Compliance
- Discontinued therapy after 1 year: 56%
- Discontinued therapy after 2 years: 68%
- References
- Viera (1999) Am Fam Physician 60:1159
- Sundaram (1997) Urology 49:932
|
|---|
| Concepts | Eicosanoid (T111)
, Pharmacologic Substance (T121)
|
| English | Caverject, Pharmacia Brand 2 of Alprostadil, Sugiran |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree